

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1. (Original) A substance, or a derivative thereof, having an ability to bind to a CD61 protein and an inhibitory effect on inflammatory cytokine production.
2. (Original) The substance or derivative of claim 1, wherein the substance is a protein.
3. (Original) The substance or derivative of claim 1, wherein the substance is an antibody.
4. (Currently Amended) The substance or derivative of claim 1, ~~2, or 3,~~ wherein the inflammatory cytokine is any one of IFN- $\gamma$ , TNF $\alpha$ , IL-1, and IL-6.
5. (Currently Amended) The substance or derivative of claim 1, ~~2, 3, or 4,~~ having an IL-10 production-inducing effect.
6. (Currently Amended) An inhibitor of inflammatory cytokine production comprising as an effective ingredient the substance or derivative of ~~any one of claims 1 to 5~~ claim 1.
7. (Original) An isolated DNA of any one of the following (a) to (d):
  - (a) a DNA of any one of SEQ ID NOs: 9 to 16;
  - (b) a DNA encoding the amino acid sequence of any one of SEQ ID NOs: 1 to 8;
  - (c) a DNA which hybridizes under stringent conditions with a DNA of any one of SEQ ID NOs: 9 to 16; and

- (d) a DNA encoding an amino acid sequence with a deletion, addition, insertion and/or substitution of one or more amino acids in the amino acid sequence of SEQ ID NOs: 1 to 8.
- 8. (Original) A vector carrying the DNA of claim 7.
- 9. (Currently Amended) A transformant carrying:
  - (1) the DNA of claim 7; or
  - (2) a vector carrying the DNA.~~carrying the DNA of claim 7 or the vector of claim 8.~~
- 10. (Original) An anti-CD61 antibody, wherein the heavy chain polypeptide is a polypeptide of the following (a) or (b):
  - (a) a polypeptide comprising the amino acid sequence of SEQ ID NO: 4; or
  - (b) a polypeptide comprising an amino acid sequence with a deletion, addition, insertion and/or substitution of one or more amino acids in the amino acid sequence of SEQ ID NO: 4 and wherein the amino acid is functionally equivalent to the amino acid sequence of SEQ ID NO: 4.
- 11. (Original) An anti-CD61 antibody comprising the amino acid sequence of the following (a) or (b) as an amino acid sequence of a CDR (complementarity determining region) of a heavy chain polypeptide:
  - (a) an amino acid sequence of any one of SEQ ID NOs: 1 to 3; or
  - (b) an amino acid sequence with a deletion, addition, insertion and/or substitution of one or more amino acids in the amino acid sequence of SEQ ID NOs: 1 to 3 and which is functionally equivalent as a CDR (complementarity determining region) to the amino acid sequence of any one of SEQ ID NOs: 1 to 3.
- 12. (Original) An anti-CD61 antibody, wherein a light chain polypeptide is a polypeptide of the following (a) or (b):
  - (a) a polypeptide comprising the amino acid sequence of SEQ ID NO: 8; or

- (b) a polypeptide comprising an amino acid sequence with a deletion, addition, insertion and/or substitution of one or more amino acids in the amino acid sequence of SEQ ID NO: 8 and wherein the amino acid is functionally equivalent to the amino acid sequence of SEQ ID NO: 8.

13. (Original) An anti-CD61 antibody comprising the amino acid sequence of the following (a) or (b) as an amino acid sequence of a CDR (complementarity determining region) of a light chain polypeptide:

- (a) an amino acid sequence of any one of SEQ ID NOs: 5 to 7; or
- (b) an amino acid sequence with a deletion, addition, insertion and/or substitution of one or more amino acids in the amino acid sequence of SEQ ID NOs: 5 to 7 and which is functionally equivalent as a CDR (complementarity determining region) to the amino acid sequence of any one of SEQ ID NOs: 5 to 7.

14. (Original) A pharmaceutical for preventing or treating an inflammatory disease, wherein the pharmaceutical comprises the inhibitor of inflammatory cytokine production of claim 6 or the anti-CD61 antibody of any one of claims 10 to 13.

15. (Original) A pharmaceutical for preventing or treating hypercytokinemia, wherein the pharmaceutical comprises the inhibitor of inflammatory cytokine production of claim 6 or the anti-CD61 antibody of any one of claims 10 to 13.

16. (Original) A method for inhibiting inflammatory cytokine production using the substance or derivative of any one of claims 1 to 5 or the anti-CD61 antibody of any one of claims 10 to 13.

17. (Currently Amended) A method for judging the effectiveness of the pharmaceutical of claim 14 ~~or 15~~ in treating an inflammatory disease ~~or hypercytokinemia~~, wherein the method comprises the step of contacting a test sample with an anti-CD61 antibody.

18. (Currently Amended) A kit for judging the effectiveness of the pharmaceutical of claim 14 ~~or 15~~ in treating an inflammatory disease ~~or hypercytokinemia~~.

19. (Original) A method of screening for a substance having an ability to bind to a CD61 protein and an inhibitory effect on inflammatory cytokine production, wherein the method comprises the steps of:

- (a) contacting an inducer of cytokine production and a test substance with a CD61-expressing cell; and
- (b) measuring the inflammatory cytokine level, comparing it with that of a control contacted with only the inducer of cytokine production, and selecting a test substance that reduced the cytokine level produced.

20. (New) A method for judging the effectiveness of the pharmaceutical of claim 15 in treating hypercytokinemia, wherein the method comprises the step of contacting a test sample with an anti-CD61 antibody.

21. (New) A kit for judging the effectiveness of the pharmaceutical of claim 15 in treating hypercytokinemia.